1-3 of 3
Meghan Macaraeg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Courtney D. DiNardo, Michael R. Savona, Ashwin Kishtagari, Amir T. Fathi, Kapil N. Bhalla, Samuel Agresta, Sarah Reilly, Caroline Almon, Murphy Hentemann, Denice Hickman, Dillon Corrigan, Meghan Macaraeg, Jessica Piel, Kim Horrigan, Salah Nabhan, Paul Martin, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 4284.
https://doi.org/10.1182/blood-2023-178090
Published: 2023
Journal Articles

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

John Carl Panetta, Sharyn D Baker, PharmD, PhD, Hagop M. Kantarjian, MD, Clinton Stewart, Pharm.D., Blake Pond, MS, Meghan Macaraeg, BS, Tolu Makinde, PhD, Sheetal Vali, PhD, Naval Daver, MD, Abhijit Ramachandran, MS, Robert Collins, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 3695.
https://doi.org/10.1182/blood.V126.23.3695.3695
Published: 2015
Journal Articles

Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant

Robert Collins, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jenny Chen, MDPhD, Meghan Macaraeg, BS, Vinoo Urity, MS, Blake Pond, MS, Abhijit Ramachandran, MS, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 4359.
https://doi.org/10.1182/blood.V126.23.4359.4359
Published: 2015